<DOC>
	<DOC>NCT01857583</DOC>
	<brief_summary>To assess the safety and pharmacokinetics of DU-176b administered to patients with severe renal impairment undergoing orthopedic surgery of the lower limbs, compared with DU-176b administered to patients with mild renal impairment (MiRI) undergoing orthopedic surgery of the lower limbs. For reference, the safety of DU-176b in patients with SRI undergoing orthopedic surgery of the lower limbs will be compared with that of fondaparinux.</brief_summary>
	<brief_title>Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<criteria>Patients with SRI or MiRI undergoing orthopedic surgery of the lower limbs Patients who are on hemodialysis or are scheduled to undergo hemodialysis during the study period Patients who are at a significantly high risk for bleeding or thromboembolism Patients who are receiving another antithrombotic therapy and are unable to suspend the therapy Patients who have evidence of hepatic function test abnormalities</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>anticoagulant</keyword>
	<keyword>DU-176b</keyword>
	<keyword>edoxaban</keyword>
	<keyword>factor Xa</keyword>
	<keyword>oral</keyword>
	<keyword>orthopedic surgery of lower limbs</keyword>
	<keyword>severe renal impairment</keyword>
</DOC>